TH3RESA: T-DM1 improves overall survival in previously treated advanced cancer patients

Molecular evolution of breast cancer during neoadjuvant chemotherapy

NSABP FB-7: Neoadjuvant therapy with neratinib plus trastuzumab in locally advanced HER2-positive breast cancer

HER2 status as predictive marker for aromatase inhibitor versus tamoxifen use in early breast cancer

Trastuzumab emtansine improves overall survival versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cance

Homologous recombination deficiency predicts neo-adjuvant chemotherapy response in triple-negative breast cancer

TAILORx: Genomic test helps identify low-risk women who do not need chemotherapy

Efficacy and gene expression results from eribulin SOLTI1007 neoadjuvant study

ER and FGFR1 interaction critical in endocrine resistant breast cancer

Interrupting breast cancer treatment for young women who desire pregnancy

Editor's choice for December 2015

Treatment outcomes in patients with invasive breast cancer treated with neoadjuvant systemic therapy and breast MR imaging